The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) is organized by AcademicCME.
Program Dates: May 11th, 2023 - May 10th, 2024
Program Overview:
This CME program, derived from content presented at the AACR Annual Meeting 2023 in Orlando, FL, will highlight the advancing role of PARP inhibitor combination therapies to improve outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC). The expert faculty, led by Dr. Alan Tan, will first review the science, mechanism of action, and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen receptor combinations to treat patients with mCRPC. Next, an analysis of current clinical trial data and clinical applications for new and emerging therapies, including PARP-inhibitors combined with androgen receptor targeted therapies, will be discussed. Following, the faculty will assess the evolving paradigm of potential treatment strategies and patient adherence factors for PARP inhibitor combinations to improve outcomes in patients with mCRPC. Upon completion of this activity, learners will gain better insight into how to treat their patients with metastatic castration-resistant prostate cancer (mCRPC) utilizing PARP inhibitor combination therapies.
Learning Objectives:
• Review the science, mechanism of action and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen receptor combinations to treat patients with mCRPC
• Analyze current clinical trial data and clinical applications for new and emerging therapies, including PARP-inhibitors combined with androgen receptor targeted therapies
• Review the evolving paradigm of potential treatment strategies and patient adherence factors for PARP inhibitor combinations to improve outcomes in patients with mCRPC
Additional details will be posted as soon as information is available.